Claims for Patent: 5,800,990

Summary for Patent: 5,800,990

Title:	Angiotensin-converting enzyme genetic variant screens
Abstract:	Rapid screening methods are described for determining human patients at risk of developing cardiovascular disease. The screening involves, for example, comparing an angiotensin-converting enzyme genomic DNA of a patient with a sequence region of angiotensin-converting enzyme gene from a person with no mutations in the region. The invention features methods of analyzing the predisposition of patients to cardiovascular disease which involves detecting small deletions, insertions, and point mutations in the angiotensin-converting enzyme gene. Small deletions, insertions, or point mutations can be detected by detecting mismatches between an angiotensin-converting enzyme genomic DNA sequence or angiotensin-converting enzyme genomic DNA-polymerase chain reaction products from a patient and a probe specific for a sequence region of angiotensin-converting enzyme gene from a person with no mutations in the region.
Inventor(s):	Raynolds; Mary V. (Englewood, CO), Perryman; M. Benjamin (Denver, CO)
Assignee:	Regents of the University of Colorado (Boulder, CO)
Application Number:	08/568,271
Patent Claims:	1. A method of detecting small deletions, insertions, or point mutations in an angiotensin-converting enzyme gene of a human patient which is used to assess the patient's risk for developing cardiovascular disease, comprising the steps of: (a) isolating an angiotensin-converting enzyme genomic DNA sequence from the patient, wherein the sequence region of the angiotensin-converting enzyme gene is a base pair region spanning intron 25 using oligonucleotide primers in the 3' region of exon 25 and the 5' region of exon 26; (b) hybridizing the angiotensin-converting enzyme genomic DNA sequence from the patient with a detectable probe specific for a sequence region of the angiotensin-converting enzyme gene from a person with no mutations in the region; and (c) detecting mismatches between the genomic DNA sequence and the probe, wherein mismatches are an indication of small deletions, insertions, or point mutations in the angiotensin-converting enzyme gene of the patient. 2. A method of detecting small deletions, insertions, or point mutations in an angiotensin-converting enzyme gene of a human patient which is used to assess the patient's risk for developing cardiovascular disease, comprising the steps of: (a) isolating an angiotensin-converting enzyme genomic DNA sequence from the patient, wherein the sequence region of the angiotensin-converting enzyme gene is a base pair region spanning intron 25 using oligonucleotide primers in the 3' region of exon 25 and the 5' region of exon 26; (b) amplifying the sequence region of the angiotensin-converting enzyme gene from the patient; (c) hybridizing the amplification products from the patient with a detectable probe specific for the sequence region of the angiotensin-converting enzyme gene of step (b) from a person with no mutations in the region; and (d) detecting mismatches between the amplification products and the probe, wherein mismatches are an indication of small deletions, insertions, or point mutations in the angiotensin-converting enzyme gene of the patient. 3. A method of detecting mutations in an angiotensin-converting enzyme gene of a human patient which is used to assess the patient's risk for developing cardiovascular disease, comprising the steps of: (a) isolating an angiotensin-converting enzyme genomic DNA sequence from the patient, wherein the sequence region of the angiotensin-converting enzyme gene is a base pair region spanning intron 25 using oligonucleotide primers in the 3' region of exon 25 and the 5' region of exon 26; (b) treating the genomic DNA sequence under denaturing conditions to obtain single-stranded DNA; (c) hybridizing the single-stranded DNA so obtained with a detectable probe specific for a sequence region of the angiotensin-converting enzyme gene from a person with no mutations in the region; and (d) detecting mismatches between the single-stranded DNA and the probe, wherein mismatches are an indication of mutations in the angiotensin-converting enzyme gene of the patient. 4. A method of detecting mutations in an angiotensin-converting enzyme gene of a human patient which is used to assess the patient's risk for developing cardiovascular disease, comprising the steps of: (a) isolating an angiotensin-converting enzyme genomic DNA sequence from the patient, wherein the sequence region of the angiotensin-converting enzyme gene is a base pair region scanning intron 25 using oligonucleotide primers in the 3' region of exon 25 and the 5' region of exon 26; (b) amplifying the sequence region of the angiotensin-converting enzyme gene from the patient; (c) treating the amplification products under denaturing conditions to obtain single-stranded DNA; (d) hybridizing the single-stranded DNA so obtained with a detectable probe specific for the sequence region of the angiotensin-converting enzyme gene of step (b) from a person with no mutations in the region; and (e) detecting mismatches between the single-stranded DNA and the probe, wherein mismatches are an indication of mutations in the angiotensin-converting enzyme gene of the patient. 5. The method according to claim 1, wherein the oligonucleotide primer sequences are d(CAACTGGACGCCGAACTC) for the 5' primer and d(GGGCGATGCCCAGGAAGA) for the 3' primer. 6. The method according to claim 2, wherein the oligonucleotide primer sequences are d(CAACTGGACGCCGAACTC) for the 5' primer and d(GGGCGATGCCCAGGAAGA) for the 3' primer. 7. The method according to claim 3, wherein the oligonucleotide primer sequences are d(CAACTGGACGCCGAACTC) for the 5' primer and d(GGGCGATGCCCAGGAAGA) for the 3' primer. 8. The method according to claim 4, wherein the oligonucleotide primer sequences are d(CAACTGGACGCCGAACTC) for the 5' primer and d(GGGCGATGCCCAGGAAGA) for the 3' primer.

Details for Patent 5,800,990

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26